Format

Send to

Choose Destination
Leuk Lymphoma. 2014 Mar;55(3):595-600. doi: 10.3109/10428194.2013.813500. Epub 2013 Jul 29.

Epidemiology of myeloproliferative neoplasms in the United States.

Author information

1
Oncology-Global Evidence and Value Development, Medical Affairs , Sanofi, Cambridge, MA , USA.

Abstract

Myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET) are three classic BCR ABL fusion gene-negative chronic myeloproliferative neoplasms (MPNs). Though rare, it is important to understand the burden of illness of these disorders for public health planning, healthcare insurers and pharmaceutical manufacturers. Therefore, we have described the incidence of MF and prevalence of MF, ET and PV in the United States between 2008 and 2010 based on data from two large health plans. The incidence of primary MF was about 1 per 100 000 per year and did not vary over the study years. The prevalence of PV (44-57 per 100 000) and ET (38-57 per 100 000) was much higher than that of MF (4-6 per 100 000) or subgroups containing MF (post-PV MF = 0.3-0.7 per 100 000; post-ET MF = 0.5-1.1 per 100 000). Additional research using other national databases and/or study designs is needed to substantiate these findings.

PMID:
23768070
DOI:
10.3109/10428194.2013.813500
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center